Iron status and the treatment of the anemia of prematurity.
Many unanswered issues regarding rhEPO therapy in prematurity remain, including which premature infants best respond to rhEPO, what the long-term effect of decreased erythrocyte transfusions is, how nutritional supplementation optimizes the effect of rhEPO, whether or not rhEpo therapy causes iron deficiency later in life, and whether or not it is safe to supplement with parenteral iron. Further study of rhEPO therapy and iron status in prematurity is necessary.
Kling
Pamela J
PJ
Department of Pediatrics, Steele Memorial Children's Research Center, 1501 N. Campbell Ave., PO # 24-5073, The University of Arizona, Tucson, AZ 85724-5073, USA. pkling@facstaff.wisc.edu
Winzerling
Joy J
JJ
D000740:Anemia / Q000378:metabolism / Q000628:therapy*; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000378:metabolism / Q000628:therapy*; D007501:Iron / Q000008:administration & dosage / Q000378:metabolism; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron